Novel pharmacological actions of Trequinsin Hydrochloride improve human sperm cell motility and function

R. C. McBrinn, J. Fraser, A. G. Hope, D. W. Gray, C. L. R. Barratt, S. J. Martins da Silva (Lead / Corresponding author), S. G. Brown (Lead / Corresponding author)

Research output: Contribution to journalArticle

15 Downloads (Pure)

Abstract

Background and Purpose: Asthenozoospermia is a leading cause of male infertility, but development of pharmacological agents to improve sperm motility is hindered by the lack of effective screening platforms and knowledge of suitable molecular targets. We have demonstrated that a high-throughput screening (HTS) strategy and established in vitro tests can identify and characterise compounds that improve sperm motility. Here, we applied HTS to identify new compounds from a novel small molecule library that increase intracellular calcium ([Ca 2+] i), promote human sperm cell motility, and systematically determine the mechanism of action. Experimental Approach: A validated HTS fluorometric [Ca 2+] i assay was used to screen an in-house library of compounds. Trequinsin hydrochloride (a PDE3 inhibitor) was selected for detailed molecular (plate reader assays, electrophysiology, and cyclic nucleotide measurement) and functional (motility and acrosome reaction) testing in sperm from healthy volunteer donors and, where possible, patients. Key Results: Fluorometric assays identified trequinsin as an efficacious agonist of [Ca 2+] i, although less potent than progesterone. Functionally, trequinsin significantly increased cell hyperactivation and penetration into viscous medium in all donor sperm samples and cell hyperactivation in 22/25 (88%) patient sperm samples. Trequinsin-induced [Ca 2+] i responses were cross-desensitised consistently by PGE 1 but not progesterone. Whole-cell patch clamp electrophysiology confirmed that trequinsin activated CatSper and partly inhibited potassium channel activity. Trequinsin also increased intracellular cGMP. Conclusion and Implications: Trequinsin exhibits a novel pharmacological profile in human sperm and may be a suitable lead compound for the development of new agents to improve patient sperm function and fertilisation potential.

Original languageEnglish
Pages (from-to)4521-4536
Number of pages16
JournalBritish Journal of Pharmacology
Volume176
Issue number23
Early online date1 Aug 2019
DOIs
Publication statusPublished - Dec 2019

Fingerprint

Sperm Motility
Cell Movement
Pharmacology
Spermatozoa
Electrophysiology
Progesterone
Asthenozoospermia
Phosphodiesterase 3 Inhibitors
Tissue Donors
Small Molecule Libraries
Acrosome Reaction
Cyclic Nucleotides
Potassium Channels
Male Infertility
Prostaglandins E
trequinsin
Fertilization
Healthy Volunteers
Calcium

Keywords

  • Calcium
  • CatSper
  • Cyclic nucleotides
  • Phosphodiesterase inhibitor
  • Sperm

Cite this

@article{deb3df136429497b9f2796c580e89836,
title = "Novel pharmacological actions of Trequinsin Hydrochloride improve human sperm cell motility and function",
abstract = "Background and Purpose: Asthenozoospermia is a leading cause of male infertility, but development of pharmacological agents to improve sperm motility is hindered by the lack of effective screening platforms and knowledge of suitable molecular targets. We have demonstrated that a high-throughput screening (HTS) strategy and established in vitro tests can identify and characterise compounds that improve sperm motility. Here, we applied HTS to identify new compounds from a novel small molecule library that increase intracellular calcium ([Ca 2+] i), promote human sperm cell motility, and systematically determine the mechanism of action. Experimental Approach: A validated HTS fluorometric [Ca 2+] i assay was used to screen an in-house library of compounds. Trequinsin hydrochloride (a PDE3 inhibitor) was selected for detailed molecular (plate reader assays, electrophysiology, and cyclic nucleotide measurement) and functional (motility and acrosome reaction) testing in sperm from healthy volunteer donors and, where possible, patients. Key Results: Fluorometric assays identified trequinsin as an efficacious agonist of [Ca 2+] i, although less potent than progesterone. Functionally, trequinsin significantly increased cell hyperactivation and penetration into viscous medium in all donor sperm samples and cell hyperactivation in 22/25 (88{\%}) patient sperm samples. Trequinsin-induced [Ca 2+] i responses were cross-desensitised consistently by PGE 1 but not progesterone. Whole-cell patch clamp electrophysiology confirmed that trequinsin activated CatSper and partly inhibited potassium channel activity. Trequinsin also increased intracellular cGMP. Conclusion and Implications: Trequinsin exhibits a novel pharmacological profile in human sperm and may be a suitable lead compound for the development of new agents to improve patient sperm function and fertilisation potential.",
keywords = "Calcium, CatSper, Cyclic nucleotides, Phosphodiesterase inhibitor, Sperm",
author = "McBrinn, {R. C.} and J. Fraser and Hope, {A. G.} and Gray, {D. W.} and Barratt, {C. L. R.} and {Martins da Silva}, {S. J.} and Brown, {S. G.}",
note = "We acknowledge and thank the Chief Scientist Office/ NHS Research Scotland (S.M.d.S.), Abertay University (R-LINCS PhD studentship for R.C.M., and sabbatical for S.G.B.) and the MRC (project grants MR/M012492/1; MR/K013343/1 C.L.R.B., S.G.B., S.M.d.S) for the funding awards.",
year = "2019",
month = "12",
doi = "10.1111/bph.14814",
language = "English",
volume = "176",
pages = "4521--4536",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley",
number = "23",

}

Novel pharmacological actions of Trequinsin Hydrochloride improve human sperm cell motility and function. / McBrinn, R. C.; Fraser, J.; Hope, A. G.; Gray, D. W.; Barratt, C. L. R.; Martins da Silva, S. J. (Lead / Corresponding author); Brown, S. G. (Lead / Corresponding author).

In: British Journal of Pharmacology, Vol. 176, No. 23, 12.2019, p. 4521-4536.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel pharmacological actions of Trequinsin Hydrochloride improve human sperm cell motility and function

AU - McBrinn, R. C.

AU - Fraser, J.

AU - Hope, A. G.

AU - Gray, D. W.

AU - Barratt, C. L. R.

AU - Martins da Silva, S. J.

AU - Brown, S. G.

N1 - We acknowledge and thank the Chief Scientist Office/ NHS Research Scotland (S.M.d.S.), Abertay University (R-LINCS PhD studentship for R.C.M., and sabbatical for S.G.B.) and the MRC (project grants MR/M012492/1; MR/K013343/1 C.L.R.B., S.G.B., S.M.d.S) for the funding awards.

PY - 2019/12

Y1 - 2019/12

N2 - Background and Purpose: Asthenozoospermia is a leading cause of male infertility, but development of pharmacological agents to improve sperm motility is hindered by the lack of effective screening platforms and knowledge of suitable molecular targets. We have demonstrated that a high-throughput screening (HTS) strategy and established in vitro tests can identify and characterise compounds that improve sperm motility. Here, we applied HTS to identify new compounds from a novel small molecule library that increase intracellular calcium ([Ca 2+] i), promote human sperm cell motility, and systematically determine the mechanism of action. Experimental Approach: A validated HTS fluorometric [Ca 2+] i assay was used to screen an in-house library of compounds. Trequinsin hydrochloride (a PDE3 inhibitor) was selected for detailed molecular (plate reader assays, electrophysiology, and cyclic nucleotide measurement) and functional (motility and acrosome reaction) testing in sperm from healthy volunteer donors and, where possible, patients. Key Results: Fluorometric assays identified trequinsin as an efficacious agonist of [Ca 2+] i, although less potent than progesterone. Functionally, trequinsin significantly increased cell hyperactivation and penetration into viscous medium in all donor sperm samples and cell hyperactivation in 22/25 (88%) patient sperm samples. Trequinsin-induced [Ca 2+] i responses were cross-desensitised consistently by PGE 1 but not progesterone. Whole-cell patch clamp electrophysiology confirmed that trequinsin activated CatSper and partly inhibited potassium channel activity. Trequinsin also increased intracellular cGMP. Conclusion and Implications: Trequinsin exhibits a novel pharmacological profile in human sperm and may be a suitable lead compound for the development of new agents to improve patient sperm function and fertilisation potential.

AB - Background and Purpose: Asthenozoospermia is a leading cause of male infertility, but development of pharmacological agents to improve sperm motility is hindered by the lack of effective screening platforms and knowledge of suitable molecular targets. We have demonstrated that a high-throughput screening (HTS) strategy and established in vitro tests can identify and characterise compounds that improve sperm motility. Here, we applied HTS to identify new compounds from a novel small molecule library that increase intracellular calcium ([Ca 2+] i), promote human sperm cell motility, and systematically determine the mechanism of action. Experimental Approach: A validated HTS fluorometric [Ca 2+] i assay was used to screen an in-house library of compounds. Trequinsin hydrochloride (a PDE3 inhibitor) was selected for detailed molecular (plate reader assays, electrophysiology, and cyclic nucleotide measurement) and functional (motility and acrosome reaction) testing in sperm from healthy volunteer donors and, where possible, patients. Key Results: Fluorometric assays identified trequinsin as an efficacious agonist of [Ca 2+] i, although less potent than progesterone. Functionally, trequinsin significantly increased cell hyperactivation and penetration into viscous medium in all donor sperm samples and cell hyperactivation in 22/25 (88%) patient sperm samples. Trequinsin-induced [Ca 2+] i responses were cross-desensitised consistently by PGE 1 but not progesterone. Whole-cell patch clamp electrophysiology confirmed that trequinsin activated CatSper and partly inhibited potassium channel activity. Trequinsin also increased intracellular cGMP. Conclusion and Implications: Trequinsin exhibits a novel pharmacological profile in human sperm and may be a suitable lead compound for the development of new agents to improve patient sperm function and fertilisation potential.

KW - Calcium

KW - CatSper

KW - Cyclic nucleotides

KW - Phosphodiesterase inhibitor

KW - Sperm

UR - http://www.scopus.com/inward/record.url?scp=85076431430&partnerID=8YFLogxK

U2 - 10.1111/bph.14814

DO - 10.1111/bph.14814

M3 - Article

C2 - 31368510

VL - 176

SP - 4521

EP - 4536

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 23

ER -